BC Innovations | Aug 9, 2017
Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG -positive cervical and breast cancers. In cervical cancer...
BC Week In Review | Jun 30, 2017
Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an expansion cohort of the Phase Ib/II BBI503-101 trial showing...
BC Week In Review | Jun 30, 2017
Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from 14 patients with hepatocellular carcinoma (HCC) in the Phase Ib/II BBI608-503-103HCC trial showing that twice-daily 160 or 240 mg oral...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Week In Review | Jun 13, 2016
Clinical News

Amcasertib: Updated Phase I data

Updated data from 13 patients with adenoid cystic carcinoma (ACC) in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that once-daily 10-300 mg oral amcasertib led to a median PFS...
BC Week In Review | May 30, 2016
Clinical News

Amcasertib: Additional Phase I data

Data from 15 patients with squamous cell carcinoma of the head and neck (SCCHN) and 5 patients with parotid/salivary tumors in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that...
BC Innovations | May 12, 2016
Tools & Techniques

Modeling with interference

While much of the focus on CRISPR-based gene editing has been on its potential to change the way genetic disorders are treated, the biggest and most immediate impact of the rapidly emerging technology so far...
BC Innovations | Apr 25, 2013
Cover Story

Super-enhancing discovery

Boston researchers have detailed a class of regulatory elements, dubbed super-enhancers, that control the expression of genes, including oncogenes, that are key to determining cellular identity. 1,2 The findings may explain how some compounds that...
BC Innovations | Aug 30, 2012
Tools & Techniques

Eliminating teratomas

A University of California, San Diego team has developed a genetic method to prevent embryonic stem cell therapies from forming cancerous teratomas following transplantation. 1 The method was safe in mice, although questions remain about...
BC Innovations | Jul 1, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Nanog homeobox (NANOG) In vitro and mouse studies suggest that inhibiting NANOG could help treat brain cancer. In a glioblastoma cell line, vector-based...
Items per page:
1 - 10 of 15